Roche gets USFDA approval of Xofluza to treat influenza in children

Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age

Kaléo announces appointments and new government business unit

Biocon Sdn. Bhd. enters Malaysia Book of Records

The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR

Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate

This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.